(2S,3R)-N-hydroxy-5-methyl-3-[[2-methylpropyl(methylsulfonyl)amino]carbamoyl]-2-(3-phenylprop-2-enyl)hexanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,3R)-N-hydroxy-5-methyl-3-[[2-methylpropyl(methylsulfonyl)amino]carbamoyl]-2-(3-phenylprop-2-enyl)hexanamide
• 化学式: C₂₂H₃₅N₃O₅S
• 分子量: 453.6
• InChiKey: BACZSFOSMGICGM-VQTJNVASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  124
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Compounds and methods for improving platelet recovery and function
  申请人：Wagner D. Denisa

  公开号：US20050019743A1

  公开（公告）日：2005-01-27

  The present invention describes an improved blood product suitable for use in transfusions comprising, in combination, blood platelets and an inhibitor of platelet glycoprotein Ibα cleavage from platelets, such as a metalloproteinase inhibitor or a TACE inhibitor. Containers for storing the improved blood product for periods of up to about 10 days, and methods for testing and using the recovered improved blood product in patient transfusions, are also provided.

  本发明描述了一种适用于输血的改良血液制品，它由血小板和血小板糖蛋白Ⅰbα裂解抑制剂（如金属蛋白酶抑制剂或TACE抑制剂）组合而成。此外，还提供了可将改良血液制品储存 10 天左右的容器，以及在患者输血中检测和使用回收的改良血液制品的方法。
• HYDRAZINE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0993442B1

  公开（公告）日：2003-04-23
• TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY
  申请人：Kenny Paraic A.

  公开号：US20090274626A1

  公开（公告）日：2009-11-05

  The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods for identifying TACE inhibitors is also provided.
• US6235787B1
  申请人：——

  公开号：US6235787B1

  公开（公告）日：2001-05-22
• [EN] COMPOUNDS AND METHODS FOR IMPROVING PLATELET RECOVERY AND FUNCTION<br/>[FR] COMPOSES ET PROCEDES D'AMELIORATION DE LA RECUPERATION ET DE LA FONCTION PLAQUETTAIRE
  申请人：BLOOD RES CENTER

  公开号：WO2004105837A2

  公开（公告）日：2004-12-09

  The present invention describes an improved blood product suitable for use in transfusions comprising, in combination, blood platelets and an inhibitor of platelet glycoprotein Iba cleavage from platelets, such as a metalloproteinase inhibitor or a TACE inhibitor. Containers for storing the improved blood product for periods of up to about 10 days, and methods for testing and using the recovered improved blood product in patient transfusions, are also provided.